Chaplin DJ - Search Results

1

Pharmacological inhibition of the hypertensive response to combretastatin A-4 phosphate in rats.

Ke Q, Bodyak N, Rigor DL, Hurst NW, Chaplin DJ, Kang PM. Ke Q, et al. Among authors: chaplin dj. Vascul Pharmacol. 2009 Nov-Dec;51(5-6):337-43. doi: 10.1016/j.vph.2009.08.004. Epub 2009 Sep 6. Vascul Pharmacol. 2009. PMID: 19737629

2

Exaggerated hypertensive response to combretastatin A-4 phosphate in hypertensive rats: Effective pharmacological inhibition by diltiazem.

Ke Q, Samad MA, Bae S, Chaplin DJ, Kang PM. Ke Q, et al. Among authors: chaplin dj. Vascul Pharmacol. 2015 Nov;74:73-79. doi: 10.1016/j.vph.2015.05.004. Epub 2015 May 16. Vascul Pharmacol. 2015. PMID: 25989107

3

Combretastatin A4 phosphate: background and current clinical status.

Young SL, Chaplin DJ. Young SL, et al. Among authors: chaplin dj. Expert Opin Investig Drugs. 2004 Sep;13(9):1171-82. doi: 10.1517/13543784.13.9.1171. Expert Opin Investig Drugs. 2004. PMID: 15330748 Review.

4

The development of combretastatin A4 phosphate as a vascular targeting agent.

Chaplin DJ, Hill SA. Chaplin DJ, et al. Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1491-6. doi: 10.1016/s0360-3016(02)03924-x. Int J Radiat Oncol Biol Phys. 2002. PMID: 12459376

5

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P).

Siemann DW, Chaplin DJ, Walicke PA. Siemann DW, et al. Among authors: chaplin dj. Expert Opin Investig Drugs. 2009 Feb;18(2):189-97. doi: 10.1517/13543780802691068. Expert Opin Investig Drugs. 2009. PMID: 19236265 Free PMC article. Review.

6

Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early effects in tumors and normal tissues.

Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MR, Dennis MF, Chaplin DJ. Tozer GM, et al. Among authors: chaplin dj. Cancer Res. 1999 Apr 1;59(7):1626-34. Cancer Res. 1999. PMID: 10197639

7

Effects of combretastatin A4 phosphate on endothelial cell morphology in vitro and relationship to tumour vascular targeting activity in vivo.

Galbraith SM, Chaplin DJ, Lee F, Stratford MR, Locke RJ, Vojnovic B, Tozer GM. Galbraith SM, et al. Among authors: chaplin dj. Anticancer Res. 2001 Jan-Feb;21(1A):93-102. Anticancer Res. 2001. PMID: 11299795

8

Eradication of colorectal xenografts by combined radioimmunotherapy and combretastatin a-4 3-O-phosphate.

Pedley RB, Hill SA, Boxer GM, Flynn AA, Boden R, Watson R, Dearling J, Chaplin DJ, Begent RH. Pedley RB, et al. Among authors: chaplin dj. Cancer Res. 2001 Jun 15;61(12):4716-22. Cancer Res. 2001. PMID: 11406542

9

Oxi4503, a novel vascular targeting agent: effects on blood flow and antitumor activity in comparison to combretastatin A-4 phosphate.

Hua J, Sheng Y, Pinney KG, Garner CM, Kane RR, Prezioso JA, Pettit GR, Chaplin DJ, Edvardsen K. Hua J, et al. Among authors: chaplin dj. Anticancer Res. 2003 Mar-Apr;23(2B):1433-40. Anticancer Res. 2003. PMID: 12820406

10

Schedule dependence of combretastatin A4 phosphate in transplanted and spontaneous tumour models.

Hill SA, Chaplin DJ, Lewis G, Tozer GM. Hill SA, et al. Among authors: chaplin dj. Int J Cancer. 2002 Nov 1;102(1):70-4. doi: 10.1002/ijc.10655. Int J Cancer. 2002. PMID: 12353236

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

210 results

Search Page

Filters